Evoke Pharma, Inc.

Historical 13F Holders

Symbol
EVOK
CUSIP
30049G203
All holders as of
Q2 2024
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 30049G203 since 12/18/2024, newest first.

Filer % of Class Filed
Bleichroeder LP 13G/A Amendment 3
10.0% 3/24/2025
Event 3/24/2025
Bleichroeder LP 13G/A Amendment 2
10.0% 3/21/2025
Event 3/19/2025
Nantahala Capital Management, LLC 13D/A Amendment 3
16.0% 2/3/2025
Event 2/3/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2024 Q2 19 3.83 M $2.02 M
2024 Q1 18 3.16 M $1.93 M
2023 Q4 13 68.8 k $72.2 k
2023 Q3 12 67.2 k $92.4 k
2023 Q2 12 59.2 k $97.4 k
2023 Q1 13 68.9 k $131 k
2022 Q4 14 60.9 k $161 k
2022 Q3 12 62.6 k $117 k
2022 Q2 14 70.5 k $228 k